Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc.

ANEB·NASDAQ

$1.72

-33%
HealthcareBiotechnology

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

At a Glance

Live Snapshot
Market Cap$70.67M
EPS-0.2500
P/E Ratio-5.74
Earnings Date02/12/2026

aneb

Account Payables

Last Annual Value

224.18K

3-Year CAGR

-16%

5-Year CAGR

%

10-Year CAGR

%

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Competitors Analysis of Account Payables

ANEB · NASDAQ
CompanyAccount Payables
CAGR 3Y
CAGR 5Y
CAGR 10Y
224.18K
-25.1%15.3%N/A 
CLNN logo
Clene Inc.
NASDAQ:CLNN
892.00K
-16.0%-14.2%N/A
0.00
N/AN/AN/A
7.21M
-21.5%-9.1%N/A
3.89M
3.3%30.4%4.1%
3.23M
-22.1%19.5%N/A
EXOZ logo
eXoZymes, Inc.
NASDAQ:EXOZ
1.24M
20.7%35.8%N/A
1.57M
41.7%10.2%N/A
443.00K
-7.0%-29.8%-10.9%
2.90M
12.6%-10.0%N/A
943.00K
-34.3%-19.7%N/A
Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. Fair Value Envelope

ANEB · NASDAQ

Our analysis suggests that ANEB has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $1.72, this represents a potential HIDDEN relative to our calculated worth for Anebulo Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $1.72